Pitcairn Co. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,405 shares of the company’s stock after selling 572 shares during the period. Pitcairn Co.’s holdings in IDEXX Laboratories were worth $996,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Swiss National Bank grew its position in shares of IDEXX Laboratories by 1.0% during the third quarter. Swiss National Bank now owns 324,500 shares of the company’s stock worth $50,457,000 after acquiring an additional 3,300 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in IDEXX Laboratories by 1.6% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 36,482 shares of the company’s stock valued at $5,673,000 after buying an additional 580 shares during the last quarter. American Century Companies Inc. grew its position in IDEXX Laboratories by 48.7% in the 3rd quarter. American Century Companies Inc. now owns 715,175 shares of the company’s stock valued at $111,203,000 after buying an additional 234,197 shares during the last quarter. State of Wisconsin Investment Board grew its position in IDEXX Laboratories by 5.7% in the 3rd quarter. State of Wisconsin Investment Board now owns 115,281 shares of the company’s stock valued at $17,925,000 after buying an additional 6,178 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. grew its position in IDEXX Laboratories by 60.1% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 830,379 shares of the company’s stock valued at $129,115,000 after buying an additional 311,712 shares during the last quarter. Institutional investors and hedge funds own 87.71% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Pitcairn Co. Lowers Stake in IDEXX Laboratories, Inc. (IDXX)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/pitcairn-co-lowers-stake-in-idexx-laboratories-inc-idxx/1696055.html.

A number of research firms recently weighed in on IDXX. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective on the stock in a research report on Wednesday, July 19th. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research report on Wednesday, August 23rd. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. IDEXX Laboratories has an average rating of “Hold” and an average price target of $173.67.

Shares of IDEXX Laboratories, Inc. (IDXX) traded down $2.51 during midday trading on Friday, hitting $147.68. 493,135 shares of the company’s stock traded hands, compared to its average volume of 557,359. The stock has a market cap of $13,099.38, a price-to-earnings ratio of 50.57, a P/E/G ratio of 2.27 and a beta of 0.46. IDEXX Laboratories, Inc. has a 52 week low of $107.59 and a 52 week high of $173.01. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. equities research analysts forecast that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the sale, the chief executive officer now directly owns 1,043,034 shares in the company, valued at approximately $161,576,396.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jonathan W. Ayers sold 58,000 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $155.00, for a total transaction of $8,990,000.00. Following the sale, the chairman now owns 1,043,034 shares in the company, valued at $161,670,270. The disclosure for this sale can be found here. Insiders have sold a total of 188,734 shares of company stock worth $28,954,266 over the last 90 days. Insiders own 2.77% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.